TRYPTAMINE THERAPEUTICS LIMITED - Announcements

2.94%

3.3¢

Market Cap $45.85M

Healthcare Biotechnology

Tryptamine Therapeutics Limited is an Australia-based clinical-stage biotechnology... Tryptamine Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. It is focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. Its lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin It intends to accomplish this through the development of an IV infusion of psilocin Its lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. It has completed phase II clinical trials for the treatment of binge eating disorder. Its pipeline products include TRP-8803 and TRP-8802.More

Announcements

Filter Results

All Price Sensitive Only

TYP	Appendix 4G and Corporate Governance Statement		29/08/25	452.53KB	Share
TYP	Appendix 4E and 2025 Annual Report	PRICE SENSITIVE	29/08/25	1.19MB	Share
TYP	Proposed issue of securities - TYP		21/08/25	16.57KB	Share
TYP	Landmark EEG Biomarker Agreement for Precision Psychiatry	PRICE SENSITIVE	21/08/25	401.28KB	Share
TYP	Application for quotation of securities - TYP		13/08/25	17.47KB	Share
TYP	$2.6m in non-dilutive capital funding secured	PRICE SENSITIVE	12/08/25	279.31KB	Share
TYP	Bioshares Biotech Summit Presentation		07/08/25	13.72MB	Share
TYP	Regulatory permits secured for world first BED trial		07/08/25	337.1KB	Share
TYP	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	31/07/25	567.11KB	Share
TYP	Patient recruitment for world first TRP-8803 trial underway	PRICE SENSITIVE	21/07/25	276.12KB	Share
TYP	Key appointments strengthen TRP-8803 clinical development		16/07/25	287.45KB	Share
TYP	Investor Presentation		26/06/25	2.64MB	Share
TYP	Binge Eating Disorder Trial receives Human Ethics approval	PRICE SENSITIVE	23/06/25	278.42KB	Share
TYP	Notification of cessation of securities - TYP		19/05/25	14.21KB	Share
TYP	Release from Escrow		16/05/25	216.84KB	Share
TYP	Initial Director's Interest Notice - HJ		14/05/25	3.22KB	Share
TYP	Final Director's Interest Notice - MD		14/05/25	3.55KB	Share
TYP	Herwig Janssen appointed as Chair and Director transition		12/05/25	293.11KB	Share
TYP	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	30/04/25	469.52KB	Share
TYP	TRP-8803 BED trial to commence with Swinburne this quarter	PRICE SENSITIVE	10/04/25	271.66KB	Share
TYP	Change in substantial holding		03/04/25	265.39KB	Share
TYP	Change of Company Secretary		31/03/25	227.2KB	Share
TYP	Change of Director's Interest Notice - DT		31/03/25	5.64KB	Share
TYP	Change of Director's Interest Notice - JC		31/03/25	5.8KB	Share
TYP	Change of Director's Interest Notice - CN		31/03/25	6.94KB	Share
TYP	Notification regarding unquoted securities - TYP		31/03/25	20.83KB	Share
TYP	Notification regarding unquoted securities - TYP		31/03/25	19.54KB	Share
TYP	Application for quotation of securities - TYP		31/03/25	17.65KB	Share
TYP	Proposed issue of securities - TYP		27/03/25	17.46KB	Share
TYP	Prospectus		27/03/25	414.89KB	Share
TYP	Results of Meeting		20/03/25	227.29KB	Share
TYP	Appendix 4D and Half Year Report for period 31 Dec 2024	PRICE SENSITIVE	27/02/25	476.74KB	Share
TYP	Update - Proposed issue of securities - TYP		13/02/25	20.17KB	Share
TYP	2024 EGM Letter of Access, Notice of Meeting and Proxy		13/02/25	763.22KB	Share
TYP	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	30/01/25	515.67KB	Share
TYP	Change of Director's Interest Notice - MD		16/01/25	4.79KB	Share
TYP	Change of Director's Interest Notice - JC		16/01/25	4.8KB	Share
TYP	Change of Director's Interest Notice - GJ		16/01/25	4.74KB	Share
TYP	Change of Director's Interest Notice - CN		16/01/25	4.97KB	Share
TYP	Notification of cessation of securities - TYP		16/01/25	14.13KB	Share
TYP	Biotech Showcase 2025 Presentation		15/01/25	2.89MB	Share
TYP	Change of Auditor		06/01/25	212.35KB	Share
TYP	Positive interim results in Phase 2a TRP-8802 IBS trial	PRICE SENSITIVE	18/12/24	296.03KB	Share
TYP	Phase 1b extension results meet study objectives	PRICE SENSITIVE	16/12/24	276.45KB	Share
TYP	Change of Director's Interest Notice - JC		04/12/24	5.92KB	Share
TYP	Change of Director's Interest Notice - CN		04/12/24	6.88KB	Share
TYP	Change of Director's Interest Notice - MD		04/12/24	5.96KB	Share
TYP	Change of Director's Interest Notice - GJ		04/12/24	5.62KB	Share
TYP	Notification regarding unquoted securities - TYP		02/12/24	27.57KB	Share
TYP	Completion of Phase 1b study of TRP-8803 in obese subjects		29/11/24	248.95KB	Share
TYP	First patient dosed in Phase 1b study into obese subjects		22/11/24	246.9KB	Share
TYP	Phase 1b determines optimal parameters for TRP-8803 use	PRICE SENSITIVE	19/11/24	410.4KB	Share
TYP	Application for quotation of securities - TYP		12/11/24	17.39KB	Share
TYP	Proposed issue of securities - TYP		12/11/24	16.92KB	Share
TYP	Prospectus		12/11/24	524.08KB	Share
TYP	Initial Director's Interest Notice - DT		08/11/24	3.42KB	Share
TYP	Final Director's Interest Notice - CB		08/11/24	3.62KB	Share
TYP	Final Director's Interest Notice - PM		08/11/24	203.71KB	Share
TYP	Results of Meeting		08/11/24	247.98KB	Share
TYP	AGM CEO Presentation		08/11/24	3.94MB	Share
TYP	Resignation of Non-Executive Director		06/11/24	222.47KB	Share
TYP	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	31/10/24	549.47KB	Share
TYP	Proposed issue of securities - TYP		30/10/24	20.3KB	Share
TYP	Proposed issue of securities - TYP		30/10/24	16.41KB	Share
TYP	$6m funding to fast track TRP-8803 clinical trial strategy	PRICE SENSITIVE	30/10/24	304.06KB	Share
TYP	Trading Halt	PRICE SENSITIVE	28/10/24	617.96KB	Share
TYP	Pause in Trading	PRICE SENSITIVE	28/10/24	116.64KB	Share
TYP	TRP-8803 doses deemed safe by SRC following phase 1b study	PRICE SENSITIVE	18/10/24	245.05KB	Share
TYP	Change in Canadian status to Designated Foreign Issuer		04/10/24	208.67KB	Share
TYP	Change of Director's Interest Notice - JC		03/10/24	4.63KB	Share
TYP	2024 AGM Notice of Meeting, Letter of Access and Proxy		30/09/24	837.34KB	Share
TYP	Annual Report to shareholders		30/09/24	1.36MB	Share
TYP	Preliminary Final Report Reporting Adjustments	PRICE SENSITIVE	30/09/24	235.96KB	Share
TYP	Appendix 4G and Corporate Governance Statement		30/09/24	693KB	Share
TYP	Director transition		23/09/24	228.03KB	Share
TYP	2024 Annual General Meeting		06/09/24	208.38KB	Share
TYP	Appointment of Chief Financial Officer		02/09/24	223.11KB	Share
TYP	Appendix 4E Preliminary Final Report	PRICE SENSITIVE	30/08/24	179.03KB	Share
TYP	Completion of patient dosing in maiden TRP-8803 trial	PRICE SENSITIVE	26/08/24	277.6KB	Share
TYP	Positive Phase 2a fibromyalgia results across all patients	PRICE SENSITIVE	12/08/24	766.11KB	Share
TYP	Trading Halt	PRICE SENSITIVE	07/08/24	614.28KB	Share
TYP	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	31/07/24	475.75KB	Share
TYP	TechKnow Invest Roadshow presentation and livestream links		30/07/24	4.52MB	Share
TYP	Appointment of Professor Phillipa Hay to TYPs SAB		30/07/24	238.89KB	Share
TYP	Psychiatry professor David Castle appointed to TYPs SAB		29/07/24	276.01KB	Share
TYP	First patient dosed in Phase 2a IBS trial at Mass General		24/07/24	262.19KB	Share
TYP	Notification of cessation of securities - TYP		22/07/24	13.95KB	Share
TYP	Phase 2a Fibromyalgia clinical study completed at U-M		10/07/24	263.07KB	Share
TYP	Maiden dosing of TRP-8803 completed in global first	PRICE SENSITIVE	01/07/24	241.09KB	Share
TYP	Dr Robin Carhart-Harris renews role as SAB Chair		26/06/24	158.27KB	Share
TYP	Appointment product registration & reimbursement strategy		19/06/24	275.76KB	Share
TYP	Change of Director's Interest Notice - JC		17/06/24	4.62KB	Share
TYP	Details of Company Address		07/06/24	212.22KB	Share
TYP	Change of Director's Interest Notice - JC		07/06/24	4.62KB	Share
TYP	Change of Director's Interest Notice - JC		06/06/24	4.62KB	Share
TYP	Change of Director's Interest Notice - JC		04/06/24	4.61KB	Share
TYP	Upcoming Expiry of Options		31/05/24	216.78KB	Share
TYP	Change of Director's Interest Notice - JC		31/05/24	4.69KB	Share
TYP	Tryptamine Therapeutics Limited commences trading on the ASX		29/05/24	268.7KB	Share
TYP	Investor Presentation May 2024 Precision Psychedelic Therapy		29/05/24	6.07MB	Share

TYP Appendix 4G and Corporate Governance Statement
29/08/25		452.53KB	Share
TYP Appendix 4E and 2025 Annual Report
29/08/25	PRICE SENSITIVE	1.19MB	Share
TYP Proposed issue of securities - TYP
21/08/25		16.57KB	Share
TYP Landmark EEG Biomarker Agreement for Precision Psychiatry
21/08/25	PRICE SENSITIVE	401.28KB	Share
TYP Application for quotation of securities - TYP
13/08/25		17.47KB	Share
TYP $2.6m in non-dilutive capital funding secured
12/08/25	PRICE SENSITIVE	279.31KB	Share
TYP Bioshares Biotech Summit Presentation
07/08/25		13.72MB	Share
TYP Regulatory permits secured for world first BED trial
07/08/25		337.1KB	Share
TYP Quarterly Activities Report and Appendix 4C
31/07/25	PRICE SENSITIVE	567.11KB	Share
TYP Patient recruitment for world first TRP-8803 trial underway
21/07/25	PRICE SENSITIVE	276.12KB	Share
TYP Key appointments strengthen TRP-8803 clinical development
16/07/25		287.45KB	Share
TYP Investor Presentation
26/06/25		2.64MB	Share
TYP Binge Eating Disorder Trial receives Human Ethics approval
23/06/25	PRICE SENSITIVE	278.42KB	Share
TYP Notification of cessation of securities - TYP
19/05/25		14.21KB	Share
TYP Release from Escrow
16/05/25		216.84KB	Share
TYP Initial Director's Interest Notice - HJ
14/05/25		3.22KB	Share
TYP Final Director's Interest Notice - MD
14/05/25		3.55KB	Share
TYP Herwig Janssen appointed as Chair and Director transition
12/05/25		293.11KB	Share
TYP Quarterly Activities Report and Appendix 4C
30/04/25	PRICE SENSITIVE	469.52KB	Share
TYP TRP-8803 BED trial to commence with Swinburne this quarter
10/04/25	PRICE SENSITIVE	271.66KB	Share
TYP Change in substantial holding
03/04/25		265.39KB	Share
TYP Change of Company Secretary
31/03/25		227.2KB	Share
TYP Change of Director's Interest Notice - DT
31/03/25		5.64KB	Share
TYP Change of Director's Interest Notice - JC
31/03/25		5.8KB	Share
TYP Change of Director's Interest Notice - CN
31/03/25		6.94KB	Share
TYP Notification regarding unquoted securities - TYP
31/03/25		20.83KB	Share
TYP Notification regarding unquoted securities - TYP
31/03/25		19.54KB	Share
TYP Application for quotation of securities - TYP
31/03/25		17.65KB	Share
TYP Proposed issue of securities - TYP
27/03/25		17.46KB	Share
TYP Prospectus
27/03/25		414.89KB	Share
TYP Results of Meeting
20/03/25		227.29KB	Share
TYP Appendix 4D and Half Year Report for period 31 Dec 2024
27/02/25	PRICE SENSITIVE	476.74KB	Share
TYP Update - Proposed issue of securities - TYP
13/02/25		20.17KB	Share
TYP 2024 EGM Letter of Access, Notice of Meeting and Proxy
13/02/25		763.22KB	Share
TYP Quarterly Activities Report and Appendix 4C
30/01/25	PRICE SENSITIVE	515.67KB	Share
TYP Change of Director's Interest Notice - MD
16/01/25		4.79KB	Share
TYP Change of Director's Interest Notice - JC
16/01/25		4.8KB	Share
TYP Change of Director's Interest Notice - GJ
16/01/25		4.74KB	Share
TYP Change of Director's Interest Notice - CN
16/01/25		4.97KB	Share
TYP Notification of cessation of securities - TYP
16/01/25		14.13KB	Share
TYP Biotech Showcase 2025 Presentation
15/01/25		2.89MB	Share
TYP Change of Auditor
06/01/25		212.35KB	Share
TYP Positive interim results in Phase 2a TRP-8802 IBS trial
18/12/24	PRICE SENSITIVE	296.03KB	Share
TYP Phase 1b extension results meet study objectives
16/12/24	PRICE SENSITIVE	276.45KB	Share
TYP Change of Director's Interest Notice - JC
04/12/24		5.92KB	Share
TYP Change of Director's Interest Notice - CN
04/12/24		6.88KB	Share
TYP Change of Director's Interest Notice - MD
04/12/24		5.96KB	Share
TYP Change of Director's Interest Notice - GJ
04/12/24		5.62KB	Share
TYP Notification regarding unquoted securities - TYP
02/12/24		27.57KB	Share
TYP Completion of Phase 1b study of TRP-8803 in obese subjects
29/11/24		248.95KB	Share
TYP First patient dosed in Phase 1b study into obese subjects
22/11/24		246.9KB	Share
TYP Phase 1b determines optimal parameters for TRP-8803 use
19/11/24	PRICE SENSITIVE	410.4KB	Share
TYP Application for quotation of securities - TYP
12/11/24		17.39KB	Share
TYP Proposed issue of securities - TYP
12/11/24		16.92KB	Share
TYP Prospectus
12/11/24		524.08KB	Share
TYP Initial Director's Interest Notice - DT
08/11/24		3.42KB	Share
TYP Final Director's Interest Notice - CB
08/11/24		3.62KB	Share
TYP Final Director's Interest Notice - PM
08/11/24		203.71KB	Share
TYP Results of Meeting
08/11/24		247.98KB	Share
TYP AGM CEO Presentation
08/11/24		3.94MB	Share
TYP Resignation of Non-Executive Director
06/11/24		222.47KB	Share
TYP Quarterly Activities Report and Appendix 4C
31/10/24	PRICE SENSITIVE	549.47KB	Share
TYP Proposed issue of securities - TYP
30/10/24		20.3KB	Share
TYP Proposed issue of securities - TYP
30/10/24		16.41KB	Share
TYP $6m funding to fast track TRP-8803 clinical trial strategy
30/10/24	PRICE SENSITIVE	304.06KB	Share
TYP Trading Halt
28/10/24	PRICE SENSITIVE	617.96KB	Share
TYP Pause in Trading
28/10/24	PRICE SENSITIVE	116.64KB	Share
TYP TRP-8803 doses deemed safe by SRC following phase 1b study
18/10/24	PRICE SENSITIVE	245.05KB	Share
TYP Change in Canadian status to Designated Foreign Issuer
04/10/24		208.67KB	Share
TYP Change of Director's Interest Notice - JC
03/10/24		4.63KB	Share
TYP 2024 AGM Notice of Meeting, Letter of Access and Proxy
30/09/24		837.34KB	Share
TYP Annual Report to shareholders
30/09/24		1.36MB	Share
TYP Preliminary Final Report Reporting Adjustments
30/09/24	PRICE SENSITIVE	235.96KB	Share
TYP Appendix 4G and Corporate Governance Statement
30/09/24		693KB	Share
TYP Director transition
23/09/24		228.03KB	Share
TYP 2024 Annual General Meeting
06/09/24		208.38KB	Share
TYP Appointment of Chief Financial Officer
02/09/24		223.11KB	Share
TYP Appendix 4E Preliminary Final Report
30/08/24	PRICE SENSITIVE	179.03KB	Share
TYP Completion of patient dosing in maiden TRP-8803 trial
26/08/24	PRICE SENSITIVE	277.6KB	Share
TYP Positive Phase 2a fibromyalgia results across all patients
12/08/24	PRICE SENSITIVE	766.11KB	Share
TYP Trading Halt
07/08/24	PRICE SENSITIVE	614.28KB	Share
TYP Quarterly Activities Report and Appendix 4C
31/07/24	PRICE SENSITIVE	475.75KB	Share
TYP TechKnow Invest Roadshow presentation and livestream links
30/07/24		4.52MB	Share
TYP Appointment of Professor Phillipa Hay to TYPs SAB
30/07/24		238.89KB	Share
TYP Psychiatry professor David Castle appointed to TYPs SAB
29/07/24		276.01KB	Share
TYP First patient dosed in Phase 2a IBS trial at Mass General
24/07/24		262.19KB	Share
TYP Notification of cessation of securities - TYP
22/07/24		13.95KB	Share
TYP Phase 2a Fibromyalgia clinical study completed at U-M
10/07/24		263.07KB	Share
TYP Maiden dosing of TRP-8803 completed in global first
01/07/24	PRICE SENSITIVE	241.09KB	Share
TYP Dr Robin Carhart-Harris renews role as SAB Chair
26/06/24		158.27KB	Share
TYP Appointment product registration & reimbursement strategy
19/06/24		275.76KB	Share
TYP Change of Director's Interest Notice - JC
17/06/24		4.62KB	Share
TYP Details of Company Address
07/06/24		212.22KB	Share
TYP Change of Director's Interest Notice - JC
07/06/24		4.62KB	Share
TYP Change of Director's Interest Notice - JC
06/06/24		4.62KB	Share
TYP Change of Director's Interest Notice - JC
04/06/24		4.61KB	Share
TYP Upcoming Expiry of Options
31/05/24		216.78KB	Share
TYP Change of Director's Interest Notice - JC
31/05/24		4.69KB	Share
TYP Tryptamine Therapeutics Limited commences trading on the ASX
29/05/24		268.7KB	Share
TYP Investor Presentation May 2024 Precision Psychedelic Therapy
29/05/24		6.07MB	Share

REFRESH

1 2 3 4

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 3.3¢		Change -0.001(2.94%)		Mkt cap ! $45.85M

Open	High	Low	Value	Volume
3.5¢	3.5¢	3.3¢	$127.5K	3.727M

Buyers (Bids)

No.	Vol.	Price($)
1	131399	3.3¢

Sellers (Offers)

Price($)	Vol.	No.
3.5¢	341700	2

View Market Depth

No.	Vol.	Price($)
1	131399	0.033
4	163875	0.032
4	406443	0.031
4	434168	0.030
4	335299	0.029

Price($)	Vol.	No.
0.035	341700	2
0.036	100000	1
0.037	345000	2
0.038	460847	3
0.039	623538	3

Last trade - 16.10pm 03/09/2025 (20 minute delay)


Last 3.3¢		Change -0.001 ( 2.94 %)
Open	High	Low	Volume
3.4¢	3.5¢	3.3¢	749437
Last updated 15.16pm 03/09/2025 ?

TYP (ASX) Chart

TRYPTAMINE THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories